tiprankstipranks
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
PremiumPress ReleasesFDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
7d ago
FDA approves Genentech’s Alecensa for adjuvant treatment
PremiumThe Fly
FDA approves Genentech’s Alecensa for adjuvant treatment
8d ago
Roche announces data from its Phase III OCARINA II study of OCREVUS
PremiumThe Fly
Roche announces data from its Phase III OCARINA II study of OCREVUS
9d ago
Genentech announces STARGLO study meets primary endpoint
PremiumThe FlyGenentech announces STARGLO study meets primary endpoint
11d ago
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
PremiumPress Releases
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
11d ago
Roche announces U.S. FDA granted BDD to its Elecsys pTau217 assay
PremiumThe Fly
Roche announces U.S. FDA granted BDD to its Elecsys pTau217 assay
15d ago
Roche receives FDA approval for the first molecular test to screen for malaria in blood donors
PremiumPress ReleasesRoche receives FDA approval for the first molecular test to screen for malaria in blood donors
1M ago
Roche’s mixed myasthenia gravis data sending these stocks in opposite directions
PremiumThe Fly
Roche’s mixed myasthenia gravis data sending these stocks in opposite directions
1M ago
Roche’s mixed myasthenia gravis data sending these stocks in opposite directions
PremiumThe Fly
Roche’s mixed myasthenia gravis data sending these stocks in opposite directions
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100